CCHT(SZ:000661) Zhi Tong Cai Jing·2025-11-13 12:44Core Viewpoint - Changchun High New Technology Industry Group Co., Ltd. (000661.SZ) announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (referred to as "JinSai Pharmaceutical"), received written notification from the U.S. Food and Drug Administration (FDA) that the clinical trial application for GenSci143 has been approved, marking a significant milestone for the company in the biopharmaceutical sector [1]. Group 1 - JinSai Pharmaceutical's GenSci143 is a dual-specific antibody-drug conjugate targeting B7-H3 and PSMA, which has potential therapeutic effects in both targeted chemotherapy and tumor immunotherapy [1]. - GenSci143 is classified as a Class 1 therapeutic biological product and is intended for the treatment of advanced solid tumors, including prostate cancer and lung cancer [1].